1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
11,350 | 11,560 | 24.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.01. | Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET) | 320 | PR Newswire | STOCKHOLM, Jan. 24, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that it will host a webcast at 11am (CET) on Monday, January 27th 2020 where CEO Jakob Lindberg... ► Artikel lesen | |
| ONCOPEPTIDES Aktie jetzt für 4€ handeln | |||||
| 24.01. | ONCOPEPTIDES AB: Oncopeptides will host a webcast on Monday, January 27[th] at 11.00 (CET) | - | Cision News | ||
| 07.01. | Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs | 246 | PR Newswire | STOCKHOLM, Jan. 7, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides.... ► Artikel lesen | |
| 07.01. | ONCOPEPTIDES AB: Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs | - | Cision News | ||
| 17.12.19 | Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ) | 261 | PR Newswire | STOCKHOLM, Dec. 17, 2019 /PRNewswire/ -- An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General... ► Artikel lesen | |
| 08.12.19 | Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 | 439 | PR Newswire | STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH... ► Artikel lesen | |
| 08.12.19 | ONCOPEPTIDES AB: Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019 | 2 | Cision News | ||
| 07.12.19 | Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 | 694 | PR Newswire | STOCKHOLM, Dec. 7, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting... ► Artikel lesen | |
| 07.12.19 | ONCOPEPTIDES AB: Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019 | - | Cision News | ||
| 06.12.19 | Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting | 292 | PR Newswire | STOCKHOLM, Dec. 6, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide... ► Artikel lesen | |
| 06.12.19 | ONCOPEPTIDES AB: Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting | - | Cision News | ||
| 02.12.19 | Oncopeptides Appoints Joseph Horvat as President North America | 186 | PR Newswire | STOCKHOLM, Dec. 2, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc.... ► Artikel lesen | |
| 02.12.19 | ONCOPEPTIDES AB: Oncopeptides appoints Joseph Horvat as President North America | - | Cision News | ||
| 14.11.19 | Extraordinary General Meeting in Oncopeptides AB (publ) | 141 | PR Newswire | STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or the... ► Artikel lesen | |
| 06.11.19 | Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 | 199 | PR Newswire | STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma... ► Artikel lesen | |
| 06.11.19 | ONCOPEPTIDES AB: Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 | - | Cision News | ||
| 31.10.19 | Number of Shares and Votes in Oncopeptides | 227 | PR Newswire | STOCKHOLM, Oct. 31, 2019
/PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise... ► Artikel lesen | |
| 31.10.19 | ONCOPEPTIDES AB: Number of shares and votes in Oncopeptides | - | Cision News | ||
| 10.10.19 | Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides | 221 | PR Newswire | STOCKHOLM , Oct. 10, 2019 /PRNewswire/ -- According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May... ► Artikel lesen | |
| 10.10.19 | ONCOPEPTIDES AB: Nomination Committee appointed in respect of AGM 2020 in Oncopeptides | - | Cision News |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 23,410 | -7,65 % | Evotec: Ruhe vor dem Sturm nach oben? | Die Aktie von Evotec tritt derzeit auf der Stelle. Allerdings ist eine Verschnaufpause nach der fast 50-Prozent-Rallye seit Mitte November 2019 auch nicht ungewöhnlich. Zumal die Aktie der Biotech-Gesellschaft... ► Artikel lesen | |
| MEDIGENE | 4,800 | -12,09 % | PTA-News: Medigene AG: Medigene nimmt an kommenden Konferenzen teil | Unternehmensmitteilung für den Kapitalmarkt München/ Martinsried (pta028/19.02.2020/22:00) - Die Medigene AG (FWB: MDG1, Prime Standard) wird an folgenden Wissenschafts- und Investoren-Konferenzen teilnehmen.... ► Artikel lesen | |
| MORPHOSYS | 109,60 | -4,45 % | Biotech Report: 4SC (VSC) und Biotest (BIO3) im Plus, MorphoSys (MOR) und Evotec (EVT) unter Druck | (shareribs.com) Frankfurt / New York 18.02.2020 - Biotech-Aktien zeigen sich im deutschen Handel uneinheitlich. 4SC und Biotest können leicht zulegen, während es für MorphoSys und Evotec abwärts geht.... ► Artikel lesen | |
| PAION | 2,210 | -1,78 % | Original-Research: PAION AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: PAION AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu PAION AG Unternehmen: PAION AG ISIN: DE000AOB65S3 Anlass der Studie: Update Empfehlung:... ► Artikel lesen | |
| BIONTECH | 27,700 | -5,59 % | Fondsmanager des Jahres ändert für die Aktie von BioNtech extrem die Prognose für 2020 (Fatale Folgen) | ||
| SANGAMO THERAPEUTICS | 6,499 | -5,29 % | Despite Skepticism, Sangamo Is A Buy | ||
| CRISPR THERAPEUTICS | 47,820 | -2,38 % | Better Buy: CRISPR Therapeutics vs. Intellia | ||
| SAREPTA THERAPEUTICS | 111,50 | -2,42 % | Sarepta Therapeutics, Inc.: Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on ... | ||
| EDITAS MEDICINE | 21,500 | -5,72 % | Better Buy: Editas Medicine vs. Intellia | ||
| INOVIO PHARMACEUTICALS | 3,680 | +5,75 % | Why Inovio Pharmaceuticals and Novavax Are Exploding Higher Today | ||
| XOMA | 25,460 | -4,21 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2019 - 1 | FOLGENDE WERTPAPIERE WERDEN AM 27.11.2019 CUM KAPITALMASSNAHME UND AM 28.11.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 27.11.2019 AND EX CAPITAL ADJUSTMENT... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 2,530 | -10,60 % | Cantor likes Celldex in premarket analyst action | ||
| BLUEBIRD BIO | 70,44 | -4,79 % | bluebird bio (BLUE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow | ||
| INTELLIA THERAPEUTICS | 11,370 | -7,79 % | Intellia (NTLA) to Report Q4 Earnings: What's in Store? | ||
| BEIGENE | 151,00 | -1,95 % | Amgen: Solider Ausblick für 2020 - Kooperation mit BeiGene geschlossen | Frankfurt (www.aktiencheck.de) - Amgen-Aktienanalyse von Analyst Tobias Gottschalt von Independent Research: Tobias Gottschalt, Aktienanalyst von Independent Research, bestätigt in einer aktuellen Aktienanalyse... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
